SkyePharma Licenses Further Solaraze Rights to Shire; Makes Investment in Micap
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 33 (Table of Contents)
Published: 3 Feb-2003
DOI: 10.3833/pdr.v2003.i33.947 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
SkyePharma licensed rights to Shire Pharmaceuticals to manufacture, distribute and market SkyePharma’s Solaraze (diclofenac) for actinic keratosis in Australia, New Zealand, South Africa and other Pacific Rim countries...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS